Stock Market & Financial Investment News

News Breaks July 30, 2012 08:21 EDT ISIS Isis Pharma target raised to $17 from $11 at Stifel Nicolaus After meeting with Isis' management, Stifel Nicolaus remains confident in near-term Kynamro regulatory decisions and longer-term peak sales estimates. The firm continues to believe that investors underestimate the company's pipeline and it maintains a Buy rating. News For ISIS From The Last 14 Days Check below for free stories on ISIS the last two weeks. Sign up for a free trial to see the rest of the stories you've been missing. June 10, 2013 07:04 EDT ISIS Xenon licenses antisense drug SEN701 from Isis Pharmaceuticals Subscribe for More Information June 6, 2013 07:01 EDT ISIS Isis Pharmaceuticals earns $6M payment from AstraZeneca Subscribe for More Information Sign up for a free trial to see the rest of the stories you've been missing.